Canadian Study Ranks Cannabis Safer Than Alcohol, Tobacco

Canadian researchers have delivered fresh ammunition for cannabis legalization advocates, with a government-funded comparative harm study placing marijuana significantly below alcohol and tobacco on societal damage metrics. The findings arrive as cannabis companies navigate complex regulatory frameworks across North America, where inconsistent scheduling and banking restrictions continue to constrain industry growth despite widespread public support.

Twenty substance abuse experts evaluated sixteen different drugs across ten harm categories, examining both individual health impacts and broader social costs. Cannabis ranked substantially lower than both alcohol and tobacco, challenging the regulatory logic that keeps marijuana federally restricted while permitting widespread alcohol and tobacco sales. This data provides concrete scientific backing for industry arguments that current drug scheduling reflects political rather than evidence-based decision-making.

The timing proves particularly relevant as cannabis operators face mounting pressure from economic headwinds and oversupply conditions. Multi-state operators like Curaleaf Holdings (CURLF) and Green Thumb Industries (GTBIF) have seen valuations compressed despite expanding state-level legalization, largely due to federal banking restrictions and 280E tax burdens that don't apply to alcohol distributors. Comparative harm data strengthens the case for federal rescheduling, which would unlock institutional investment and normalize banking relationships.

Canada's legal cannabis market offers a preview of post-prohibition dynamics, though early results show mixed outcomes. Licensed producers initially struggled with pricing competition from illicit markets, forcing consolidation among smaller operators. However, companies like Canopy Growth Corporation (CGC) have stabilized operations by focusing on premium products and international expansion opportunities that remain unavailable to U.S. operators under current federal restrictions.

The study's conclusions align with growing institutional recognition that cannabis prohibition imposes higher social costs than regulated legalization. As more jurisdictions examine tax revenue potential and criminal justice savings, comparative harm research provides policymakers with empirical justification for treating cannabis more like alcohol than controlled substances. For cannabis investors, such data represents a fundamental shift in the policy debate that could accelerate federal reform timelines and unlock the sector's institutional investment potential.